Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACADIA PharmaceuticalsFRA:DR6 -2.29%80 Graham Number is €16.06 as of Jun. 2026, which is 100% below its 10-year median of 1.70. GuruFocus rates FRA:DR6 with a GF Score™ of 80/100 and a GF Value™ of €22.56 (Fairly Valued). The stock has 9 warning signs investors should review. Among 252 Biotechnology companies, ACADIA Pharmaceuticals ranks better than 60.71% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
ACADIA Pharmaceuticals (FRA:DR6) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
ACADIA Pharmaceuticals's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Jun. 2026 )
=
22.15
/
16.06
=
1.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
ACADIA Pharmaceuticals Graham Number Related Terms
ACADIA Pharmaceuticals Graham Number Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:DR6 vs LEGN, TNGX, CAI: Graham Number Comparison
For the Biotechnology subindustry, ACADIA Pharmaceuticals's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals Price-to-Graham-Number vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals (FRA:DR6) has a Graham Number of €16.06 as of Jun. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on ACADIA Pharmaceuticals and its competitors. This is 845% above median its historical median of 1.70. Over the past decade, ACADIA Pharmaceuticals' Graham Number has ranged from 1.22 to 5.14. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #99 out of 252 companies in the Biotechnology industry, placing it in the top 39.3%.
Is ACADIA Pharmaceuticals' Graham Number too high?
ACADIA Pharmaceuticals' current Graham Number of €16.06 is 845% above median its 10-year median of 1.70. Over the past 10 years, this metric has ranged from a low of 1.22 to a high of 5.14. Based on the distribution chart, ACADIA Pharmaceuticals ranks #99 out of 252 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ACADIA Pharmaceuticals has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Graham Number compare to LEGN and TNGX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #99 out of 252 companies for Graham Number. This puts ACADIA Pharmaceuticals in the upper half of its industry. The industry median Graham Number is 1.75. Historically, ACADIA Pharmaceuticals' own Graham Number has ranged from 1.22 to 5.14 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Biotechnology company?
The median Graham Number among Biotechnology companies is 1.75, based on 252 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on ACADIA Pharmaceuticals and its competitors. For the Biotechnology industry, the median Graham Number is 1.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACADIA Pharmaceuticals's current Graham Number is €16.06, which is 845% above median its own 10-year median of 1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (FRA:DR6) is currently considered Fairly Valued. The stock's GF Value™ is €22.56, compared to a current price of €22.15 — trading 1.8% below its estimated fair value. The current Graham Number is €16.06, which is 845% above median its 10-year median of 1.70. ACADIA Pharmaceuticals' overall GF Score™ is 80/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For ACADIA Pharmaceuticals (FRA:DR6), the current Graham Number is €16.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (FRA:DR6) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued.
The current stock price of €22.15 is trading 1.8% below its estimated GF Value™ of €22.56.
GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.
Key valuation signals for FRA:DR6:
Graham Number: €16.06 (845% above median its 10-year median of 1.70)
GF Value™: €22.56 vs. price of €22.15 (1.8% below fair value)
No single metric tells the full story. See the FRA:DR6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
80GF Score
Get the complete analysis for FRA:DR6
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DR6 has been successfully added to your 
